MedDataX Logo

EuGeni Rapid Antigen Test for the Qualitative Detection of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Causing COVID19 Disease in Compliance With the World Health Organization (WHO)

NCT ID: NCT05618561

Last Updated: 2024-12-06

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Total Enrollment

599 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-07-26

Study Completion Date

2022-11-02

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Rapid antigen detection (RAD) tests are used to perform rapid diagnosis of SARS-CoV-2 infection based on a qualitative approach. RAD tests detect the viral antigen by the immobilized coated SARS-CoV-2 antibody placed on the device. The results of these tests are available in a short time, reducing the workload in diagnostic hospitals and laboratories and improving the turn-around time.

EuGeni SARS-CoV-2 Antigen Rapid Diagnostic Test is an in vitro Diagnostic (IVD) medical device intended to be used for the qualitative detection of SARS-CoV-2 nucleocapsid antigen. The result from this IVD test identifies the presence or absence of the SARS-CoV-2 antigen as an aid for the diagnosis of COVID-19 infection.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The EuGeni SARS-CoV-2 Antigen (Ag) Rapid Detection Test (RDT) is a test strip based on lateral flow technology which utilizes nanoparticles, doped with europium, as the fluorescence reporter system. The test strip is housed in a cassette which is read by the EuGeni AX-2X-S Reader, a portable instrument that reads EuGeni fluorescent lateral flow tests.

The test line contains an immobilized monoclonal mouse antibody to capture SARS-CoV-2 antigen and the control line contains an immobilized control anti-mouse antibody.

The test sample is added to the sample well of the test cassette and then reconstitutes the dried europium nanoparticle antibody conjugate from the conjugate pad. The sample flows along the test strip by capillary action.

If the sample contains SARS-CoV-2 antigen, it binds to the antibody-labelled europium nanoparticle. When the sample flows past the test line, the europium bound antigen is captured by the second anti-SARS-CoV-2 antibody immobilized on the test line. A fluorescent signal detected by the EuGeni AX-2X-S Reader at this test line indicates that the specimen is SARS-CoV-2 antigen Positive.

If the sample does not contain SARS-CoV-2 antigen, the europium-labelled anti-antigen antibody will not bind to the test line. This indicates that the specimen is SARS-CoV-2 antigen Negative.

The sample continues to flow along the strip and when it passes over the control line, antibody-labelled europium nanoparticles are captured by the immobilized anti-mouse antibody. The control line must be detected by the EuGeni AX-2X-S Reader for the test to be valid. If the control line is not detected, the test is considered invalid and must be repeated using another test cassette.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

SARS-CoV-2 Infection

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

covid19

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Nasopharyngeal specimen collection arm

Specimens collected in nasopharyngeal form from positive subjects with symptoms and negative subjects hospitalized and negative subjects with respiratory symptoms.

EuGeni SARS-CoV-2 Antigen Rapid Diagnostic Test

Intervention Type DIAGNOSTIC_TEST

Subjects have two swabs taken for analysis, one (combined or nasopharyngeal) with the kit under investigation and the other (by standard of care) for analysis with PCRl.

Combined nasal mid-turbinate and throat specimen collection arm

Specimens collected in combined nasal mid-turbinate form from positive subjects with symptoms and negative subjects hospitalized and negative subjects with respiratory symptoms.

EuGeni SARS-CoV-2 Antigen Rapid Diagnostic Test

Intervention Type DIAGNOSTIC_TEST

Subjects have two swabs taken for analysis, one (combined or nasopharyngeal) with the kit under investigation and the other (by standard of care) for analysis with PCRl.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

EuGeni SARS-CoV-2 Antigen Rapid Diagnostic Test

Subjects have two swabs taken for analysis, one (combined or nasopharyngeal) with the kit under investigation and the other (by standard of care) for analysis with PCRl.

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Specimens from subjects over 12 years old agreeing to participate in the study and with a legal representative able to provide informed consent, OR;
2. Specimens from subjects over 18 years old able to provide informed consent.
3. Specimens collected with nasopharyngeal swabs, OR;
4. Combined nasal mid-turbinate and throat specimen collection.

Exclusion Criteria

1. Specimens and testing methods that are not deemed to be in line with gold-standard RT-PCR standards.
2. Specimens stored for over 2 hours at 2-8 ºC temperature between collection and testing with EuGeni SARS-CoV-2 Ag RDT.
3. Specimens stored for over 5 days at -20ºC between collection and testing with RT-PCR.
4. Specimens stored for over 24h at 4ºC between collection and testing with RT-PCR.
5. Contamination and/or deterioration of the specimen which, in the opinion of the investigator, may affect its handling and/or analysis.
6. The subject is deemed unsuitable to participate in the study by the investigator.
Minimum Eligible Age

12 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

AnteoTech Ltd

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

M. Antonia Sánchez Calavera

Role: PRINCIPAL_INVESTIGATOR

C.S. Fuentes Norte

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Institut Virion

Split, , Croatia

Site Status

Laiko General Hospital

Athens, , Greece

Site Status

Centro de Salud Fuentes Norte

Zaragoza, Aragon, Spain

Site Status

Centro de Salud Torre Ramona

Zaragoza, Aragon, Spain

Site Status

Hospital Universitario de A Coruña (CHUAC)

A Coruña, Galicia, Spain

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Croatia Greece Spain

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Study Protocol

View Document

Document Type: Statistical Analysis Plan

View Document

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CT013

Identifier Type: -

Identifier Source: org_study_id